Form 4: Olema Pharmaceuticals Director Cyrus Harmon Sells Shares Under 10b5-1 Trading Plan
SEC Form 4 Filing
Director Cyrus Harmon of Olema Pharmaceuticals sold shares of common stock on multiple dates in late May and early June under a pre-arranged 10b5-1 trading plan.
Summary
- Cyrus Harmon, a director at Olema Pharmaceuticals, sold shares of the company's common stock.
- The sales occurred on May 31, 2024, June 3, 2024, and June 4, 2024.
- These transactions were executed under a 10b5-1 trading plan adopted on May 16, 2023.
- On May 31, 2024, 15,000 shares were sold at a weighted average price of $9.41.
- On June 3, 2024, 5,000 shares were sold at a weighted average price of $10.93.
- On June 4, 2024, 5,000 shares were sold at a weighted average price of $12.33.
- Following these transactions, Harmon directly owns 781,283 shares and indirectly owns 122,028 shares through Harmon Family Investors LLC.
Sentiment
Score: 5
Explanation: The sentiment is neutral as the transactions were pre-planned under a 10b5-1 trading plan. It doesn't necessarily indicate a negative outlook on the company, but it's not a positive signal either.
Negatives
- The director's sale of shares could be perceived negatively by some investors.
Risks
- Continued sales by insiders could put downward pressure on the stock price.
Industry Context
Insider sales are a common occurrence in publicly traded companies. The use of a 10b5-1 trading plan allows insiders to sell shares over a predetermined period, mitigating concerns about trading on non-public information.
Key Dates
| Date | Description |
|---|---|
| 2023/05/16 | Date of adoption of the 10b5-1 trading plan. |
| 2024/05/31 | Date of first reported transaction (sale of 15,000 shares). |
| 2024/06/03 | Date of second reported transaction (sale of 5,000 shares). |
| 2024/06/04 | Date of third reported transaction (sale of 5,000 shares) and date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.